OptimizeRx Corp
OPRXOptimizeRx Corp AI Insights
Informational only. Not investment advice.Snapshot
- Goodwill of 70.9M is 58% of equity and 66% of intangibles (113.3M) - acquisition-heavy model with impairment risk if growth stalls[Goodwill]
- FCF TTM of 11.6M vs net income of 34K - earnings near zero but cash generation strong; interest expense (5.6M) consuming operating profit[Free Cash Flow TTM]
- Revenue 3Y CAGR of 20% vs industry median 5.4% - outpacing peers but P/E of 1,403x signals market pricing in massive future growth[Total Revenue 3Y Growth]
Watch Triggers
- Interest Expense TTM: Rises above 6.5M or interest coverage falls below 1.0x — Already consuming most operating income; any increase threatens FCF
- Goodwill: Any impairment charge or acquisition adding to 70.9M balance — 58% of equity; impairment would devastate book value
- Total Revenue 3Y Growth: Falls below 15% CAGR — Valuation requires sustained 20%+ growth; deceleration reprices stock
Bull Case
Gross margin TTM 65.3% vs industry 43.7% - software-like economics with minimal capex (258K TTM) enables 10.6% FCF yield on EV
20% revenue CAGR (3Y and 5Y) in healthcare IT niche with operating leverage - operating margin 6.2% vs industry 2% shows scale benefits emerging
Bear Case
P/E of 1,403x and P/B of 30.5x require flawless execution; tangible book value only 9M vs 273M market cap - 96% of value is intangible
Net income TTM of 34K on 109.5M revenue (0.03% margin) - interest burden and amortization consuming operating profits entirely
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage OPRX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
FCF conversion will compress as interest costs rise or revenue growth decelerates
- Interest expense 5.6M TTM on 28.6M debt (19.6% effective rate)
- Operating income 6.8M barely covers interest
- Revenue growth must sustain 20%+ to maintain coverage
Public Strategies Rankings
See how OptimizeRx Corp ranks across different investment strategies.
Leverage OPRX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
OPRX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$248.31M | — | ||
$257.4M | — | ||
1,276 | — | ||
$109.51M | +24.2% | — | |
$0.01 | — | ||
6.17% | +19.6% | — | |
0.03% | +27.4% | — | |
$11.57M | — | ||
0.00 | +21.0% | — | |
Beta 5Y (Monthly) | unknown | — |
OPRX Dividend History
OPRX Stock Splits
OPRX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/07/25 | 09/30/25 | 10-Q | |
08/08/25 | 06/30/25 | 10-Q | |
05/13/25 | 03/31/25 | 10-Q | |
03/20/25 | 12/31/24 | Unknown | |
11/14/24 | 09/30/24 | 10-Q | |
08/15/24 | 06/30/24 | 10-Q | |
05/15/24 | 03/31/24 | 10-Q | |
04/15/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/12/23 | 03/31/23 | 10-Q | |
03/10/23 | 12/31/22 | 10-K | |
11/08/22 | 09/30/22 | 10-Q | |
08/09/22 | 06/30/22 | 10-Q | |
05/09/22 | 03/31/22 | 10-Q | |
02/28/22 | 12/31/21 | 10-K | |
11/09/21 | 09/30/21 | 10-Q | |
08/04/21 | 06/30/21 | 10-Q | |
05/06/21 | 03/31/21 | 10-Q | |
03/08/21 | 12/31/20 | 10-K | |
11/09/20 | 09/30/20 | 10-Q | |
08/05/20 | 06/30/20 | 10-Q | |
05/06/20 | 03/31/20 | 10-Q | |
03/26/20 | 12/31/19 | 10-K | |
11/05/19 | 09/30/19 | 10-Q | |
08/07/19 | 06/30/19 | 10-Q | |
05/08/19 | 03/31/19 | 10-Q | |
03/12/19 | 12/31/18 | 10-K | |
11/05/18 | 09/30/18 | 10-Q | |
08/07/18 | 06/30/18 | 10-Q | |
05/02/18 | 03/31/18 | 10-Q | |
03/08/18 | 12/31/17 | 10-K | |
11/02/17 | 09/30/17 | 10-Q | |
08/01/17 | 06/30/17 | 10-Q | |
05/03/17 | 03/31/17 | 10-Q | |
03/08/17 | 12/31/16 | 10-K | |
11/07/16 | 09/30/16 | 10-Q | |
08/08/16 | 06/30/16 | 10-Q | |
05/09/16 | 03/31/16 | 10-Q | |
03/15/16 | 12/31/15 | 10-K | |
11/12/15 | 09/30/15 | 10-Q | |
08/11/15 | 06/30/15 | 10-Q | |
05/14/15 | 03/31/15 | 10-Q | |
03/31/15 | 12/31/14 | 10-K | |
11/13/14 | 09/30/14 | 10-Q | |
08/14/14 | 06/30/14 | 10-Q | |
05/15/14 | 03/31/14 | 10-Q | |
03/31/14 | 12/31/13 | 10-K | |
11/14/13 | 09/30/13 | 10-Q | |
08/12/13 | 06/30/13 | 10-Q | |
05/15/13 | 03/31/13 | 10-Q | |
03/12/13 | 12/31/12 | 10-K | |
11/14/12 | 09/30/12 | 10-Q | |
08/14/12 | 06/30/12 | 10-Q | |
05/15/12 | 03/31/12 | 10-Q | |
03/30/12 | 12/31/11 | 10-K | |
11/14/11 | 09/30/11 | 10-Q | |
08/17/11 | 06/30/11 | 10-Q | |
05/16/11 | 03/31/11 | 10-Q | |
03/31/11 | 12/31/10 | 10-K | |
11/23/11 | 09/30/10 | 10-Q/A | |
11/16/10 | 09/30/10 | 10-Q | |
08/16/10 | 06/30/10 | 10-Q | |
05/17/10 | 03/31/10 | 10-Q | |
03/31/10 | 12/31/09 | 10-K | |
11/23/09 | 09/30/09 | 10-Q | |
08/13/09 | 06/30/09 | 10-Q | |
05/22/09 | 03/31/09 | 10-Q | |
04/15/09 | 12/31/08 | 10-K | |
11/23/09 | 09/30/08 | 10-Q | |
08/13/09 | 06/30/08 | 10-Q | |
05/22/09 | 03/31/08 | 10-Q |